A targeted IL-15 fusion protein with potent anti-tumor activity.

Abstract:

:IL-15 has been actively investigated for its potential in tumor immunotherapy. To enhance the anti-tumor activity of IL-15, the novel PFC-1 construct was designed, which comprises the following 3 parts: (1) IL-15Rα fused with IL-15 to enhance IL-15 activity, (2) an Fc fragment to increase protein half-life, and (3) an integrin-targeting RGD peptide to enhance tumor targeting. PFC-1 showed tumor cell targeting without compromising IL-15 activity. PFC-1 also had potent anti-tumor activities in xenograft models, suggesting the potential application of this multi-functional fusion protein in tumor therapy.

journal_name

Cancer Biol Ther

journal_title

Cancer biology & therapy

authors

Chen S,Huang Q,Liu J,Xing J,Zhang N,Liu Y,Wang Z,Li Q

doi

10.1080/15384047.2015.1071739

subject

Has Abstract

pub_date

2015-01-01 00:00:00

pages

1415-21

issue

9

eissn

1538-4047

issn

1555-8576

journal_volume

16

pub_type

杂志文章
  • Vasculogenic mimicry is a marker of poor prognosis in prostate cancer.

    abstract::We investigated the role of vasculogenic mimicry (VM) in the progression of prostate cancer (PCa). Ninety-six patients who had undergone prostatectomy for treatment of PCa and for whom a complete record of clinical and follow-up data were available were reviewed. VM and matrix metalloproteinase-2 (MMP-2) were detected...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.19602

    authors: Liu R,Yang K,Meng C,Zhang Z,Xu Y

    更新日期:2012-05-01 00:00:00

  • Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.

    abstract::Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims to elucidate this mechanism of c-Met TKI resistance by investigating key mTOR and Wnt signaling proteins in melanoma ce...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.29451

    authors: Etnyre D,Stone AL,Fong JT,Jacobs RJ,Uppada SB,Botting GM,Rajanna S,Moravec DN,Shambannagari MR,Crees Z,Girard J,Bertram C,Puri N

    更新日期:2014-09-01 00:00:00

  • Upregulation of the androgen receptor during prostate cancer progression.

    abstract::The androgen receptor is one of the central factors in mediating prostate cancer progression and is an important target for treatment. Several possible mechanisms have been put forth as to how it promotes this process. In the January 2004 issue of Nature Medicine, Chen et al. report that the androgen receptor is consi...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.3.3.785

    authors: Singh A,Figg WD

    更新日期:2004-03-01 00:00:00

  • Silencing of heparanase by siRNA inhibits tumor metastasis and angiogenesis of human breast cancer in vitro and in vivo.

    abstract::Expression of the heparanase gene is associated with invasive, angiogenic and metastatic potential of diverse malignant tumors and cell lines. Here we used RNA interference strategies to evaluate the role of human heparanase in breast malignancy and to explore the therapeutic potential of its specific targeting. The s...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.4.3888

    authors: Zhang ZH,Chen Y,Zhao HJ,Xie CY,Ding J,Hou YT

    更新日期:2007-04-01 00:00:00

  • Verotoxin-1 induction of apoptosis in Gb3-expressing human glioma cell lines.

    abstract::The aim of this study was to examine the cytotoxicity and mechanism of apoptosis induction of verotoxin-1 (VT-1) in human glioma cell lines. VT-1 is a member of the shiga-toxin family expressed by some serotypes of Escherichia coli and Shigella dysenteriae. Shiga-toxins have been shown to induce apoptosis by binding t...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.9.3173

    authors: Johansson D,Johansson A,Grankvist K,Andersson U,Henriksson R,Bergström P,Brännström T,Behnam-Motlagh P

    更新日期:2006-09-01 00:00:00

  • Contribution of dendritic cells' FcgammaRI and FcgammaRIII to cross-presentation of tumor cells opsonized with the anti-MHC class I monoclonal antibodies.

    abstract::Dendritic cells (DC) operate through an immature (iDC) step (where tumor antigens are internalized) and a mature step (mDC) (where tumor antigens (TA) are cross-presented to naive TA-specific cytotoxic T lymphocyte (CTL) progenitors). Receptors by which cellbound antigens can access the DC cross-presentation pathway i...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.12.4973

    authors: Signorino E,Brusa D,Granata R,Malavasi F,Ferrone S,Matera L

    更新日期:2007-12-01 00:00:00

  • Obesity promotes melanoma tumor growth: role of leptin.

    abstract::Epidemiological studies suggest that obesity increases the risk of developing several cancers, including melanoma. Obesity increases the expression of angiogenic factors, such as leptin, that may contribute to tumor growth. However, a direct cause and effect relationship between obesity and tumor growth has not been c...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.19.9650

    authors: Brandon EL,Gu JW,Cantwell L,He Z,Wallace G,Hall JE

    更新日期:2009-10-01 00:00:00

  • Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer.

    abstract:PURPOSE:Fibroblast Activation Protein (FAP) is a tumor fibroblast protease that has been shown to potentiate colorectal cancer growth. The clinical impact of FAP inhibition was tested using Val-boroPro (Talabostat), the first clinical inhibitor of FAP enzymatic activity, in a phase II study of patients with metastatic ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.11.4874

    authors: Narra K,Mullins SR,Lee HO,Strzemkowski-Brun B,Magalong K,Christiansen VJ,McKee PA,Egleston B,Cohen SJ,Weiner LM,Meropol NJ,Cheng JD

    更新日期:2007-11-01 00:00:00

  • Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trial.

    abstract:OBJECTIVES:To evaluate the 6-mo overall survival, safety and tolerability of lenalidomide in combination with standard gemcitabine as first-line treatment for patients with metastatic pancreatic cancer. METHODS:Eligibility included: previously untreated metastatic adenocarcinoma of the pancreas with metastases incurab...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,多中心研究

    doi:10.4161/cbt.23625

    authors: Infante JR,Arkenau HT,Bendell JC,Rubin MS,Waterhouse D,Jones GT,Spigel DR,Lane CM,Hainsworth JD,Burris HA 3rd

    更新日期:2013-04-01 00:00:00

  • Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer.

    abstract::Breast cancer is one of the most commonly diagnosed malignancies in women. Despite the remarkable success of mammography screening and use of adjuvant systemic therapy, it is estimated that approximately 200,000 new diagnoses will be made this year and 40,000 deaths will occur due to this disease (American Cancer Soci...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.9.17677

    authors: Rosca EV,Koskimaki JE,Pandey NB,Wolff AC,Popel AS

    更新日期:2011-11-01 00:00:00

  • Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells.

    abstract::Aberrant methylation of tumour suppressor genes is associated with the progression to a blast crisis in chronic myeloid leukaemia (CML). Methyl-CpG-binding domain protein 2 (MBD2) has been studied as a "reader" of DNA methylation in many cancers, but its role in CML is unclear. We constructed cell models of a homozygo...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1450113

    authors: Cheng L,Tang Y,Chen X,Zhao L,Liu S,Ma Y,Wang N,Zhou K,Zhou J,Zhou M

    更新日期:2018-08-03 00:00:00

  • Identification of recurrence-related serum microRNAs in hepatocellular carcinoma following hepatectomy.

    abstract::Hepatocellular carcinoma (HCC) is one of the most deadly tumors. Prognosis of patients with HCC is generally poor due to the high recurrence rate. In the present study, TaqMan Real-time PCR microRNA Array was used to identify differentially expressed miRNAs from 10 tumor tissue samples (5 from recurrence group vs. 5 f...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071730

    authors: Wang L,Liu M,Zhu H,Rong W,Wu F,An S,Liu F,Feng L,Wu J,Xu N

    更新日期:2015-01-01 00:00:00

  • Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review.

    abstract::Although targeted therapy directed toward driver mutations has produced a significant efficacy benefit for patients with non-small cell lung cancer (NSCLC), many patients do not possess mutations associated with the approved targeted drugs. Angiogenic agents play an important role in the therapeutic strategy for advan...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.1080/15384047.2017.1414757

    authors: Wu F,Zhang S,Gao G,Zhao J,Ren S,Zhou C

    更新日期:2018-03-04 00:00:00

  • Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations.

    abstract::Celecoxib exhibits cancer preventive and therapeutic effects in animal models and clinical trials. It presumably acts through selective inhibition of cyclooxygenase-2 (COX-2) and subsequent reduction of prostaglandin (PG) synthesis. However, the concentrations of celecoxib required for growth inhibition and apoptosis ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.4.4.1618

    authors: Sun SY,Schroeder CP,Yue P,Lotan D,Hong WK,Lotan R

    更新日期:2005-04-01 00:00:00

  • Chitosan hydrogel for localized gene silencing.

    abstract:OBJECTIVE:To achieve effective delivery of siRNA into target cells in vivo, we have developed a novel approach of siRNA delivery by using local drug delivery systems. RESULTS:The chitosan hydrogel (CH-HG) displayed a liquid-solid phase transition in a temperature-dependent manner and formed an endothermic hydrogel in ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.9.15185

    authors: Han HD,Mora EM,Roh JW,Nishimura M,Lee SJ,Stone RL,Bar-Eli M,Lopez-Berestein G,Sood AK

    更新日期:2011-05-01 00:00:00

  • Small molecule inhibitors of IRES-mediated translation.

    abstract::Many genes controlling cell proliferation and survival (those most important to cancer biology) are now known to be regulated specifically at the translational (RNA to protein) level. The internal ribosome entry site (IRES) provides a mechanism by which the translational efficiency of an individual or group of mRNAs c...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1071729

    authors: Vaklavas C,Meng Z,Choi H,Grizzle WE,Zinn KR,Blume SW

    更新日期:2015-01-01 00:00:00

  • DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.

    abstract::Current treatment modalities for pancreatic carcinoma afford only modest survival benefits. TRAIL, as a potent and specific inducer of apoptosis in cancer cells, would be a promising new treatment option. However, since not all pancreatic cancer cells respond to TRAIL, further improvements and optimizations are still ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/15384047.2014.972183

    authors: Yu R,Albarenque SM,Cool RH,Quax WJ,Mohr A,Zwacka RM

    更新日期:2014-01-01 00:00:00

  • Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation.

    abstract::We investigated the expression of annexin-1 (ANXA1) in thyroid carcinoma cell lines and in thyroid cancers with a different degree of differentiation. The highest level of ANXA1 expression examined by Western blotting was detected in the papillary carcinoma cells (NPA) and in the follicular cells (WRO). On the other h...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.6.2700

    authors: Petrella A,Festa M,Ercolino SF,Zerilli M,Stassi G,Solito E,Parente L

    更新日期:2006-06-01 00:00:00

  • Comparitive study of efficacy, tolerability of four field box technique vs. two field anterior posterior technique in locally advanced carcinoma cervix--a prospective analysis.

    abstract:PURPOSE:The pelvic failure rate decreases with increase in the radiation dose but the complications increase. The four field pelvic technique has a theoretical advantage of providing a higher tumor dose with less dose to the surrounding normal tissue thus reducing the complications. RESULT:Eighty-three patients comple...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,随机对照试验

    doi:10.4161/cbt.8.9.8129

    authors: Gupta D,Shukla P,Bisht SS,Aggarwal A,Dhawan A,Pant MC,Bhatt ML,Gupta R,Srivastava K,Gupta S,Srivastava M

    更新日期:2009-05-01 00:00:00

  • Prediction of proapoptotic anticancer therapeutic response in vivo based on cell death visualization and TRAIL death ligand-receptor interaction.

    abstract::Tumor growth is often associated with insufficient apoptosis. The Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand (TRAIL) and its proapoptotic receptors death receptor 4 (DR4) and DR5 agonistic monoclonal antibodies are being developed as targeted therapeutics because they kill cancer cells while sparing...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.12.4.17174

    authors: Zhou L,Wang W,Dicker DT,Humphreys RC,El-Deiry WS

    更新日期:2011-08-15 00:00:00

  • DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

    abstract::MDM2 antagonists stabilize and activate wild-type p53, and histone methyltransferase (HMT) inhibitors reduce methylation on histone lysines and arginines. Both MDM2 antagonists and HMT inhibitors are being developed as cancer therapeutics. Wild-type p53 expressing HCT116 colon cancer cells were resistant to apoptosis ...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2018.1433500

    authors: Zhou Y,Perez RE,Duan L,Maki CG

    更新日期:2018-06-03 00:00:00

  • EphA2 as a promoter of melanoma tumorigenicity.

    abstract::The greatest health threat from malignant melanoma is death due to metastatic disease. Consequently, the identification of markers predictive of metastatic disease is essential for identifying new therapeutic targets. EphA2, a protein tyrosine kinase receptor commonly expressed in epithelial cells, has been found to b...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.8.3.7485

    authors: Margaryan NV,Strizzi L,Abbott DE,Seftor EA,Rao MS,Hendrix MJ,Hess AR

    更新日期:2009-02-01 00:00:00

  • Mitogen-activated protein kinase phosphatase-1 inhibition and sustained extracellular signal-regulated kinase 1/2 activation in camptothecin-induced human colon cancer cell death.

    abstract::Camptothecins are commonly used chemotherapeutics; in some models, they enhance signaling via the mitogen-activated protein kinase (MAPK) pathway through effects on upstream kinases. To evaluate the impact of camptothecin (CPT) on MAPKs in human colon cancer, we studied HCT116 and CaCo2 colon cancer cells. We found th...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.26044

    authors: Lee M,Young Kim S,Kim J,Kim HS,Kim SM,Kim EJ

    更新日期:2013-11-01 00:00:00

  • 17beta-estradiol and tamoxifen stimulate rapid and transient ERK activationin MCF-7 cells via distinct signaling mechanisms.

    abstract::Traditionally, estrogen signaling was thought to be mediated strictly through genomic pathways. Recently, however, it has been demonstrated that estrogen stimulation of cells leads to rapid nongenomic effects including ERK activation. While the precise mechanism of this action is still under investigation, it is known...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.5.12.3378

    authors: Visram H,Greer PA

    更新日期:2006-12-01 00:00:00

  • CIP2A expression and localization in oral carcinoma and dysplasia.

    abstract:AIMS:Oral squamous cell carcinoma (OSCC) is the most prevalent malignancy of the oral cavity resulting in severe morbidity and mortality. To date only few proteins have been suggested as potential biomarkers or targets for this type of cancer. Cancerous inhibitor of PP2A (CIP2A) is a protein expressed in epithelial tis...

    journal_title:Cancer biology & therapy

    pub_type: 评论,杂志文章

    doi:10.4161/cbt.10.7.12895

    authors: Katz J,Jakymiw A,Ducksworth MK,Stewart CM,Bhattacharyya I,Cha S,Chan EK

    更新日期:2010-10-01 00:00:00

  • Multiplying therapies and reducing toxicity in metastatic melanoma.

    abstract::Prior to 2011, only 2 systemic treatments were approved for the treatment of melanoma and these had limited efficacy. In the past 4 years, 6 novel agents have received FDA approval. Herein, we will focus on 4 recently published NEJM papers reporting the results of clinical trials, comprising 4 agents targeting the MAP...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2015.1046650

    authors: Massey PR,Prasad V,Figg WD,Fojo T

    更新日期:2015-01-01 00:00:00

  • Wild-type and mutant p53 proteins interact with mitochondrial caspase-3.

    abstract::Caspases play a key role in the apoptotic pathway by virtue of their ability to cleave key protein substrates within the dying cell. Caspases are produced as inactive zymogens, and need to become proteolytically processed in order to become active. A key executioner caspase, caspase-3, has previously been found to exi...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.11.8.14906

    authors: Frank AK,Pietsch EC,Dumont P,Tao J,Murphy ME

    更新日期:2011-04-15 00:00:00

  • Ototoxicity in patients with invasive ductal breast cancer who were treated with docetaxel: report of two cases.

    abstract::Docetaxel is an important anti-microtubule agent used to treat a variety of solid tumors, including breast cancer; notably, docetaxel-containing regimens improve outcomes for patients in metastatic, adjuvant, and neoadjuvant settings. However, the effectiveness of docetaxel in clinical practice can be compromised by s...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.1080/15384047.2020.1831370

    authors: Xuan L,Sun B,Meng X,Liu C,Cong Y,Wu S

    更新日期:2020-11-01 00:00:00

  • Molecular basis of pathogenesis, prognosis and therapy in chronic lymphocytic leukaemia.

    abstract::B-cell chronic lymphocytic leukemia (CLL) is caused by the abnormal accumulation of non-functional B-cells in peripheral blood and bone marrow. However, the precise aetiology and mechanism of the disease are unclear. Recently, progress has been made in the identification of both the genetic deficiencies and environmen...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章,评审

    doi:10.4161/cbt.7.2.5262

    authors: Chen J,McMillan NA

    更新日期:2008-02-01 00:00:00

  • Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy.

    abstract::There is an urgent need to develop new strategies to treat ovarian cancer, the most deadly gynecologic malignancy. Histone deacetylase (HDAC) inhibitors are emerging as novel therapeutic drugs in the treatment of a variety of cancers, including those resistant to standard chemotherapy. Since there are multiple HDAC is...

    journal_title:Cancer biology & therapy

    pub_type: 杂志文章

    doi:10.4161/cbt.6.5.4007

    authors: Khabele D,Son DS,Parl AK,Goldberg GL,Augenlicht LH,Mariadason JM,Rice VM

    更新日期:2007-05-01 00:00:00